Skip to main content
SP5007,680.61+0.36%DOW53,603.45+0.35%NASDAQ26,153.53+0.67%BTC$78,685.00-0.39%ETH$2,458.82-1.88%GOLD$4,680.20-0.37%OIL$82.40-3.07%
Smart Investors Daily
Sign InSign Up Free
EV

NASDAQ · EVOK

Evoke Pharma, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$11.00

Up+$11.00 (+0.00%)

Updated Aug 25, 2026, 1:33 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
18.86M
P/E ratio
-5.19
Dividend yield
0.00%
52-week range
$1.94 – $11.00
Volume
47.11K
Avg. volume
94.97K

Price performance

EVOK price history

1M range · 0 trading sessions · Daily adjusted prices

EVOK does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest EVOK news

The latest Smart Investors Daily articles mentioning EVOK.

Stock researchCompany · Overview

EVOK research

Overview

Company profile and research snapshot.

Company profile

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
EVOK recent ratings
DateFirmRatingTarget
Jun 22, 2020HC Wainwright & Co.Buy—
Mar 5, 2019H.C. WainwrightNeutral—
Oct 6, 2017Seaport GlobalBuy—
Jan 30, 2017Laidlaw & Co.Buy—
Jan 5, 2017Rodman & RenshawBuy—
Open full forecast

News briefing

No generated briefing is available yet.

proactiveinvestors.co.uk · Dec 10, 2025

William Hill owner Evoke puts business up for sale as gambling taxes weigh

Shares in William Hill owner Evoke PLC (LSE:EVOK) bounced 8% to 23.83p after the bookmaker confirmed that it is putting all or part of the company up for sale. A strategic review has been launched, the company said in a short statement, including "a range of potential alternatives to maximise shareholder value, including, but not limited to a potential sale of the group, or some of the company's assets and/or business units".

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By